Company: PACB
Filing Date: 2025-03-17
Form Type: 10-K
Source: 0001299130-25-000061
Chunk: 980

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-03-17
Form: 10-K
Item: Item 8
Chunk 980
---
 — 189,200 Issuance of common stock in conjunction with equity plans5,8366 15,313 — — 15,319 Share-based compensation expense—— 72,118 — — 72,118 Balance at December 31, 2023267,744$268 $2,539,892 $219 $(1,839,075)$701,304 Net loss—— — — (309,851)(309,851)Other comprehensive income—— — 203 — 203 Issuance of common stock in conjunction with equity plans6,2226 7,697 — — 7,703 Issuance of common stock in conjunction with convertible notes exchange20,45220 36,179 36,199 Share-based compensation expense—— 71,036 — — 71,036 Balance at December 31, 2024294,418$294 $2,654,804 $422 $(2,148,926)$506,594 

See accompanying notes to the consolidated financial statements.

Fiscal 2024 Form 10-K87

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.CONSOLIDATED STATEMENTS OF CASH FLOWSYears Ended December 31,(in thousands)202420232022Cash flows from operating activitiesNet loss$(309,851)$(306,735)$(314,248)Adjustments to reconcile net loss to net cash used in operating activitiesDepreciation 13,774 11,463 9,480 Amortization of intangible assets27,412 8,261 913 Amortization of right-of-use assets12,165 6,810 6,925 Share-based compensation expense71,036 72,118 78,613 Impairment charges184,500 — — Merger-related compensation expense— 3,395 — Loss on extinguishment of debt— 2,033 — Gain on debt restructuring(154,407)— — Accretion of discount and amortization of premium on marketable securities, net(13,044)(12,840)(244)Change in the estimated fair value of contingent consideration(850)15,060 2,377 Inventory provision4,618 10,584 6,027 Deferred income taxes(205)(11,424)—